BRIM Biotechnology, Inc. (TPE:6885)
Taiwan · Delayed Price · Currency is TWD 29.10
+0.55 (1.93%)
Nov 13, 2026, 1:30 PM CST
BRIM Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 12.55 | 5.49 | 0.33 | 0.09 | 0.53 | 0.36 | |
Revenue Growth | 295.59% | 1548.65% | 270.00% | -82.89% | 46.11% | -99.60% |
Cost of Revenue | 14.6 | 4.24 | 0.31 | - | - | - |
Gross Profit | -2.05 | 1.25 | 0.02 | 0.09 | 0.53 | 0.36 |
Selling, General & Admin | 154.14 | 123.68 | 106.31 | 112.33 | 72.96 | 44.97 |
Research & Development | 309.63 | 330.54 | 238.5 | 581.88 | 145.89 | 48.6 |
Operating Expenses | 463.77 | 454.22 | 344.81 | 694.22 | 218.85 | 93.58 |
Operating Income | -465.82 | -452.97 | -344.79 | -694.13 | -218.33 | -93.22 |
Interest Expense | -0.45 | -0.5 | -0.09 | -0.15 | -0.08 | -0.11 |
Interest & Investment Income | 23.51 | 31.76 | 32.9 | 21.8 | 0.83 | 0.5 |
Earnings From Equity Investments | -15.02 | -13.47 | -27.03 | -24.59 | -62.62 | -47.94 |
Currency Exchange Gain (Loss) | -15.66 | -15.66 | 23.53 | 9.03 | 5.9 | -1.76 |
Other Non Operating Income (Expenses) | -8.39 | -0.07 | - | 0 | 0.02 | 4.21 |
EBT Excluding Unusual Items | -481.83 | -450.92 | -315.47 | -688.04 | -274.28 | -138.32 |
Gain (Loss) on Sale of Assets | - | - | - | 0.01 | - | 32.87 |
Other Unusual Items | 0.01 | 0.01 | - | - | - | - |
Pretax Income | -481.83 | -450.91 | -315.47 | -688.02 | -274.28 | -105.45 |
Income Tax Expense | 0.03 | - | - | - | - | - |
Earnings From Continuing Operations | -481.86 | -450.91 | -315.47 | -688.02 | -274.28 | -105.45 |
Minority Interest in Earnings | 41.39 | 14.46 | - | - | - | - |
Net Income | -440.46 | -436.45 | -315.47 | -688.02 | -274.28 | -105.45 |
Net Income to Common | -440.46 | -436.45 | -315.47 | -688.02 | -274.28 | -105.45 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 132 | 132 | 117 | 101 | 71 | 59 |
Shares Outstanding (Diluted) | 132 | 132 | 117 | 101 | 71 | 59 |
Shares Change | 1.92% | 12.74% | 16.02% | 41.02% | 20.23% | 0.72% |
EPS (Basic) | -3.35 | -3.32 | -2.70 | -6.84 | -3.85 | -1.78 |
EPS (Diluted) | -3.35 | -3.32 | -2.70 | -6.84 | -3.85 | -1.78 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -12.07 | -329.97 | -282.14 | -599.15 | -172.98 | -113.35 |
Free Cash Flow Per Share | -0.09 | -2.51 | -2.42 | -5.96 | -2.43 | -1.91 |
Gross Margin | -16.34% | 22.77% | 6.61% | 100.00% | 100.00% | 100.00% |
Operating Margin | -3712.29% | -8250.89% | -103539.04% | -771250.00% | -41506.84% | -25893.06% |
Profit Margin | -3510.23% | -7949.94% | -94735.74% | -764468.89% | -52143.92% | -29291.39% |
Free Cash Flow Margin | -96.20% | -6010.38% | -84726.73% | -665723.33% | -32885.74% | -31485.83% |
EBITDA | -426.11 | -417.6 | -340.5 | -693.12 | -218.02 | -93.01 |
D&A For EBITDA | 39.71 | 35.37 | 4.29 | 1.01 | 0.31 | 0.2 |
EBIT | -465.82 | -452.97 | -344.79 | -694.13 | -218.33 | -93.22 |